Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

ticagrelor

- PMLiVE

Final NICE backing for MabThera in rare condition

Roche drug available in England and Wales to treat rare form of vasculitis

- PMLiVE

AstraZeneca launches delivery service for Nexium

Expands its US direct-to-patient programme

- PMLiVE

NICE refuses to back Zaltrap as Sanofi exhausts its options

Patient access scheme and appeal fail to overcome cost concerns

Otsuka’s Samsca heads clutch of Japanese approvals

Astellas' Xtandi, AstraZeneca's Forxiga and Takeda's Zacras also given the green light

National Institute for Health and Care Excellence NICE logo

Mixed cancer news from NICE

Agency backs Janssen’s myeloma drug but denies Bayer’s Xofigo in prostate cancer

AstraZeneca to develop mHealth cardiovascular services

Willwork with Vodafone in a new global partnership

National Institute for Health and Care Excellence NICE logo

Boehringer cancer drug on course for NHS use in UK

NICE backs Giotrif in draft guidance

- PMLiVE

Dawn of the new world

What the new NHS means for pharma and healthcare comms

- PMLiVE

McCarthy leaves NHS England

Policy director set for move to the University of Bradford

UK flag

UK gets its own ‘breakthrough’ status for early medicines access

But concerns remain over funding

- PMLiVE

Teva backs UK’s dementia drive with $21m investment

Pharma company will support National Institute for Health Research

National Institute for Health and Care Excellence NICE logo

NICE denies pharma influence on statin guidance

Responds to accusations committee members were ‘in the pay’ of drug firms

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links